Today, Vita Therapeutics published an open letter to the LGMD2A/R1 community announcing some important changes to their development plans.
WATCH: Sarepta presents webinar about new natural history study for individuals living with LGMD2A/R1
Sarepta Therapeutics recently joined C3 to present a community webinar titled “Journey Update for the LGMD2A/R1 Calpainopathy Community.” During the webinar, Sarepta discussed the essential role for natural history studies throughout the drug development process. They then shared the design
Volker Straub appointed to C3 Scientific Advisory Board
Coalition to Cure Calpain 3 (C3) is pleased to share that Dr. Volker Straub has been appointed to our Scientific Advisory Board (SAB), joining Dr. Melissa Spencer (Chair), Dr. Kevin Campbell, Dr. Eric Hoffman, and Dr. Louis Kunkel. Professor Volker
English
አማርኛ
العربية
简体中文
繁體中文
Dansk
Nederlands
Français
Deutsch
עִבְרִית
हिन्दी
Italiano
日本語
ភាសាខ្មែរ
한국어
كوردی
मराठी
Norsk bokmål
Polski
Português
ਪੰਜਾਬੀ
Русский
Español
Svenska
தமிழ்
తెలుగు
Türkçe